Imatinib with c-Abl Kinase

Source: Wikipedia

Why?

The discovery of Imatinib (Glivec) launched the new era of *magic bullets* to treat all types of cancers. Currently about 30 kinase inhibitors are FDA approved to treat cancers and autoimmune diseases. The discovery of Imatinib was based on structure-based drug design, including co-crystal structure of it with c-Abl kinase domain. The kinase inhibitors, by virtue of selective-targettng, exhibit much less side effects than chemotherapy.—Mukund Mehrotra